4 documents found, page 1 of 1
Urgent request for pretomanid label expansion to align with WHO guidelines and ...
Kuksa, L; Andrejak, C; Haecker, B; Bothamley, G; Calcagno, A; Cirillo, DM; Duarte, R; Fatima, R; Ferlazzo, G; Guglielmetti, L; Günther, G; Hewison, CPretomanid is a key anti-TB drug included in the WHO list of essential medications. The current EMA-approved label for pretomanid restricts its use to the regimen comprising bedaquiline, pretomanid and linezolid (BPaL) and only for extensively drug-resistant-TB or multidrug-resistant TB, “when antibiotics used for the latter form of TB do not work or cause unacceptable side effects.” This restricted use implies...
Rifapentine access in Europe: growing concerns over key tuberculosis treatment ...
Guglielmetti, L; Günther, G; Leu, C; Cirillo, D; Duarte, R; Garcia-Basteiro, AL; Goletti, D; Jankovic, M; Kuksa, L; Maurer, FP; Méchaï, F; Tiberi, S[No abstract available]
The Tuberculosis Network European Trials group (TBnet) ERS Clinical Research Co...
van Leth, F; Brinkmann, F; Cirillo, DM; Dheda, K; Duarte, R; Guglielmetti, L; Kuksa, L; Lange, C; Mitnick, C; Skrahina, A; Zaman, K; Bothamley, Gn/a
Management of patients with multidrug-resistant tuberculosis
Lange, C; Aarnoutse, RE; Alffenaar, JWC; Bothamley, G; Brinkmann, F; Costa, J; Chesov, D; van Crevel, R; Dedicoat, M; Dominguez, J; Duarte, RThe emergence of multidrug-resistant tuberculosis (MDR-TB; defined as resistance to at least rifampicin and isoniazid) represents a growing threat to public health and economic growth. Never before in the history of mankind have more patients been affected by MDR-TB than is the case today. The World Health Organization reports that MDR-TB outcomes are poor despite staggeringly high management costs. Moreover, t...